Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience

J Dermatolog Treat. 2023 Dec;34(1):2268764. doi: 10.1080/09546634.2023.2268764. Epub 2023 Oct 11.

Authors

Luigi Gargiulo^{1

2}, Luciano Ibba^{1

2}, Carlo A Vignoli^{1

2}, Silvia M Ferrucci³, Santo R Mercuri⁴, Piergiorgio Malagoli⁵, Angelo V Marzano^{3

6}, Mauro Barbareschi⁶, Vittoria G Bianchi⁴, Mario Valenti^{1

2}, Antonio Costanzo^{1

2}, Alessandra Narcisi¹

Affiliations

¹ Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
² Department of Biomedical Sciences, Humanitas University, Milan, Italy.
³ Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
⁴ Dermatology and Cosmetology Unit, IRCCS San Raffaele Hospital, Milan, Italy.
⁵ Department of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, Italy.
⁶ Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.

PMID: 37818648
DOI: 10.1080/09546634.2023.2268764

No abstract available

Publication types

Multicenter Study

MeSH terms

Alopecia Areata* / drug therapy
Azetidines* / therapeutic use
Humans
Purines / therapeutic use

Substances

baricitinib
Purines
Azetidines

Supplementary concepts

Diffuse alopecia